SCIDOT-05. DEVELOPING VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET PATHOLOGICALLY EXPOSED NEURAL ECM TO TREAT GLIOBLASTOMA

INTRODUCTION: The median survival of gliobastoma (GBM) patients remains less than two years despite aggressive treatments. Current targeted GBM therapies demonstrate initial therapeutic benefit; however, patients relapse due to therapeutic resistance and failure to eliminate GBM cells at the invasiv...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: J Umlauf, Benjamin, A Clark, Paul, M Lajoie, Jason, V Georgieva, Julia, Bremner, Samantha, R Herrin, Brantley, V Shusta, Eric, S Kuo, John
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Abstracts from the 3rd Sno-Scidot Joint Conference on Therapeutic Delivery to the CNS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846694/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.1146
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg